LOUISVILLE, CO--(Marketwire - September 24, 2008) - GlobeImmune, Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has been accepted for presentation at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place Oct. 31 through Nov. 4, 2008, in San Francisco.
